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Malignant melanoma is an extremely aggressive cancer arising from melanocytes, associated with the development
of metastases in up to 20% of patients. Although the liver is a frequent metastatic site of malignant melanoma,
primary hepatic melanoma (PHM) is rare. The treatment of PHM is controversial, and the prognosis for affected
patients remains poor. We present two PHM patients who underwent partial hepatectomy at our institution and
review the clinical and pathological data from these cases. Our results suggest that it is difficult to make a preoperative
diagnosis of PHM without pathological results. For patients with resectable PHM, surgical resection is a potentially
curative treatment.
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The American Cancer Society estimated that in 2012,
76,250 new cases of melanoma were diagnosed in the
United States and 9,180 patients died from the disease [1].
Ninety percent of all melanomas are of cutaneous origin
[2]. Although the liver is a frequent site of metastases
from melanomas, primary hepatic melanoma (PHM) is
rare. In this report, we present two patients with PHM
who underwent partial hepatectomy in our institution and
review the literature addressing this topic.Case presentation
Case 1
A 60-year-old male presented with a 1-month history
of upper abdominal discomfort. Physical examination
found no palpable lymph nodes, scars or pigmented
patches. The abdomen was soft with no tenderness and
no palpable liver or spleen. There was no history of an
excised pigmented lesion or history of eye surgery.
Liver function tests did not show signs of liver injury
(alanine aminotransferase: 25 U/L, aspartate transamin-
ase: 39 U/L, albumin: 36.4 g/L). The tumour markers* Correspondence: drzhangchengwu@126.com
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unless otherwise stated.alpha-fetoprotein (AFP) (3.49 μg/L), carcinoembryonic anti-
gen (2.04 μg/L), carbohydrate antigen 19 to 9 (12.8 U/mL)
as well as complete blood count (red blood cells: 4.82 ×
1012/L, white blood cells: 7.37 × 109/L, platelets: 223 ×
109/L) were all in the normal range. Abdominal ultrason-
ography revealed a mass in the right lobe of the liver with
liquid at its centre. Computed tomography (CT) showed a
14 × 14 cm mixed-attenuation mass with a pseudocapsule
and central low attenuation in the right lobe of the liver
(Figure 1A). Magnetic resonance imaging (MRI) demon-
strated an isointense high-signal lesion in the right lobe of
the liver on T1-weighted imaging (T1W1), with mixed
low- and high-signal intensity on T2-weighted imaging
(T2W1) (Figure 1B). The mass showed peripheral en-
hancement with a contrast agent during the arterial and
portal venous phases on both CT and MRI.
The patient underwent right hemi-hepatectomy and
resection of the lymph nodes in the hepatoduodenal
ligament. A 15 × 15 cm solid-cystic tumour was found in
the right lobe of the liver, and metastasized lymph nodes
were found in the hepatoduodenal ligament (Figure 2A).
The tumour had ruptured preoperatively, and intraperi-
toneal haemorrhage was found in the region of the right
liver during the operation. Microscopic examination re-
vealed the mass to contain elongated malignant cellsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Imaging findings of case 1. (A), (B) Computed tomography and magnetic resonance imaging showing a mass in the right liver lobe.
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anin pigment (Figure 2B). Postoperative immunostain-
ing of the liver tumour established the diagnosis of
malignant melanoma; the tumour was focally strong-
positive for HMB45 and diffuse-positive for S100
(Figure 2C,D), with no staining of cytokeratin (CK) and
AFP. The patient had no history of melanocytic or pig-
mented lesions. No other melanomas were identified
despite rigorous physical examination, which included
anal and ophthalmologic examination in addition to a
complete cutaneous evaluation. Further tests, including
ophthalmoscopy, examination of the anogenital region,
and upper and lower gastrointestinal endoscopy, were
all normal. The patient recovered well and receivedFigure 2 Pathological findings of case 1. (A) A black solid-cystic tumour
contained elongated malignant cells with +melanin pigment (×200). (C) Th
malignant cells were immunostained with S100 (×400).interleukin-2 (IL-2) therapy postoperatively, but died
4 months after surgery from intra-peritoneal recurrence
of the tumour.
Case 2
A 72-year-old male patient was admitted to our hospital
because of a right hepatic lesion found on ultrasound
scan; he did not have abdominal discomfort, fever
or weight loss. Tumour markers (AFP: 2.4 μg/L, carci-
noembryonic antigen: 3.6 μg/L and carbohydrate antigen
19 to 9: 2.9 U/mL), complete blood count (red blood
cells: 4.74 × 1012/L, white blood cells: 6.23 × 109/L, plate-
lets: 181 × 109/L) and liver function tests (alanine amino-
transferase: 11 U/L, aspartate transaminase: 25 U/L,was found in the right hemi-hepatectomy specimen. (B) The mass
e malignant cells were immunostained with HMB45 (×400). (D) The
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puted tomography demonstrated multiple high-attenuation
lesions in the right lobe of the liver (Figure 3A). MRI
showed a heterogeneous high-signal mass on T2W1
with a central low-signal area in the right lobe of the
liver; the centre of the lesion had low signal intensity
on T1W1 (Figure 3B). With a contrast agent, the mass
showed enhancement in the arterial phase and no en-
hancement in the portal venous phase.
The patient underwent right hemi-hepatectomy as well
as lymph node resection in the hepatoduodenal ligament.
Gross pathologic examination demonstrated a 14 × 12 cm
solid-cystic lesion in the right liver (Figure 4A) and
enlarged, black lymph nodes in the hepatoduodenal liga-
ment. Microscopic examination revealed the lesion to
be full of elongated malignant cells (Figure 4B), and the
lesion was positive on immunostaining with HMB45
and S100 (Figure 4C,D), negative with CK and AFP.
Based on these results, the patient was diagnosed with
malignant melanoma. No other melanoma sites were
detected despite rigorous physical examination, includ-
ing anal and ophthalmologic examination in addition to
complete cutaneous evaluation. Further tests, including
positron emission tomography-CT (PET-CT), ophthal-
moscopy, examination of the anogenital region, and upper
and lower gastrointestinal endoscopy, were all normal. An
uneventful postoperative recovery was achieved, and the
patient was treated with IL-2. The patient has experienced
a 12-month disease-free interval up to the present.
Discussion
Malignant melanoma is an extremely aggressive neo-
plasm of melanocytes [3]. It usually originates in the epi-
thelial tissues of the skin, retina and anorectal canal, but
it sometimes originates in rare primary locations such as
the gastrointestinal tract, genital tract, accessory nasal
cavity and parotid. Primary hepatic melanoma is an ex-
tremely rare neoplasm; to our knowledge, only 12 cases
have been reported. The origin of PHM is unclear, asFigure 3 Imaging findings of case 2. (A), (B) Computed tomography an
liver lobe.there are no melanocytes in the liver. Some authors
have suggested that these neoplasms arise from ectopic
melanocytes that have undergone malignant transform-
ation [4,5].
There is no consensus regarding the diagnosis of
PHM. Contemporary diagnostic criteria include the
following: 1) hepatic melanoma confirmed histologically
and immunohistochemically, 2) exclusion of other pri-
mary malignant melanomas, and 3) the absence of a pre-
vious cutaneous tumour (that was destroyed or excised
without histologic examination). It is difficult to identify
this disease without histologic or immunohistochemical
results because there is no typical clinical picture for
patients with PHM. In our experience, certain imaging
findings on CT or MRI suggest a PHM: 1) a detectable
pseudocapsule around the liver mass; 2) slight enhance-
ment of the mass during both arterial and portal venous
stages; and 3) on MRI, the mass tends to present as a
heterogeneous hyperintense lesion on T1WI and as a
hypointense lesion on T2WI. However, these imaging
findings only lead us to a presumptive diagnosis of
PHM; histology and immunohistochemical staining
remain the 'gold standard' criteria for the definitive
diagnosis of PHM.
Both of our cases were preoperatively misdiagnosed as
hepatocellular carcinomas. The clinical, laboratory, and
imaging findings were so nonspecific that it was difficult
for the surgeons to make a diagnosis without pathological
results. The accurate diagnosis of these lesions without
pathological results remains an ongoing challenge to be
solved in the future. Our experience demonstrates that,
for liver masses with the imaging findings mentioned
above, a diagnosis of PHM should be considered.
The optimal treatment and the prognosis for PHM re-
main largely unknown. Surgical resection has been well
documented to be the best choice for treating isolated
hepatic melanoma metastases [6-9]. Based on our re-
sults, we hypothesise that surgical intervention may also
be the best choice for patients with resectable PHM. Wed magnetic resonance imaging showing multiple lesions in the right
Figure 4 Pathological findings of case 2. (A) Multiple black solid-cystic lesions were found in the right hemi-hepatectomy specimen. (B) The
mass contained elongated malignant cells with melanin pigment (×400). (C) The malignant cells were immunostained with HMB45 (×400).
(D) The malignant cells were immunostained with S100 (×400).
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the hepatoduodenal ligament in both of these cases. The
tumour number, size, location and treatment were simi-
lar in the two patients. However, dramatically different
survival times were achieved. The first patient died
4 months after surgery, while the other remains disease-
free up through the present (12 months after surgery).
Our results suggest that complete surgical extirpation
may be potentially curative in some cases (case 2). An-
other point is that tumour rupture, which is correlated
with intraperitoneal metastasis, is an important factor
influencing survival in patients with PHM (case 1). In
both cases, we found enlarged lymph nodes in the hepa-
toduodenal ligament, indicating that PHM has a high in-
cidence of lymph node metastasis. We suggest that R0
resection of the hepatic tumour with lymph node resec-
tion in the hepatoduodenal ligament is necessary for the
radical resection of PHM.
Until now, no conventional treatments have shown ef-
ficacy in the treatment of PHM. Large doses of IL-2 have
been suggested by the National Comprehensive Cancer
Network as the treatment of choice for advanced melan-
oma. Chemotherapy (dacarbazine) has shown limited ef-
ficacy [10]. However, several new molecular targeted
therapies such as nivolumab and ipilimumab have been
applied in phase III trials with encouraging results
[11,12]. Additionally, some doctors have reported thattreatment with surgical resection followed by adoptive
cell therapy shows some benefit for patients with malig-
nant melanoma [9].Conclusion
We present two cases of PHM, a rare disease that has
been addressed by few reports in the past. Primary hep-
atic melanoma should be considered as a diagnosis in
patients with the imaging findings described in this re-
port. For appropriately-selected PHM patients, surgical
resection represents a feasible, safe and potentially cura-
tive treatment option.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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